Lytix Biopharma ("Lytix"),  is pleased to announce that it will host a Capital
Markets Day for investors, analysts and media on Wednesday, June 1, 2022. 

The event will be open for physical attendance in Oslo, Norway, as well as a
live webcast. It is scheduled to start at 14.00 CET, and is expected to last
approximately two hours, including Q&A.

Speakers will be Ted White, CEO of Verrica Pharmaceuticals Inc. ("Verrica"),
Gary Goldenberg, CMO of Verrica, Aurelien Marabelle, visiting professor at
Stanford University and an internationally recognized expert on intratumoral
cancer treatment, and Øystein Rekdal, CEO of Lytix Biopharma.

Verrica has an exclusive worldwide license agreement with Lytix to develop and
commercialize its lead compound, LTX-315, for dermatologic oncology conditions,
and the first patient has been dosed in Verrica's Phase II study evaluating
LTX-315 for intratumoral treatment of basal cell carcinoma (skin cancer). At the
CMD the focus will be... See attached flyer. 

Further details of the agenda and registration details will follow.